vs

Side-by-side financial comparison of AMREP CORP. (AXR) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $14.6M, roughly 1.4× AMREP CORP.). AMREP CORP. runs the higher net margin — 21.6% vs -66.3%, a 87.9% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs -8.7%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -13.6%).

AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

AXR vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.4× larger
LUNG
$20.6M
$14.6M
AXR
Growing faster (revenue YoY)
AXR
AXR
+102.5% gap
AXR
93.8%
-8.7%
LUNG
Higher net margin
AXR
AXR
87.9% more per $
AXR
21.6%
-66.3%
LUNG
Faster 2-yr revenue CAGR
LUNG
LUNG
Annualised
LUNG
-0.5%
-13.6%
AXR

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
AXR
AXR
LUNG
LUNG
Revenue
$14.6M
$20.6M
Net Profit
$3.1M
$-13.7M
Gross Margin
77.9%
Operating Margin
20.6%
-40.9%
Net Margin
21.6%
-66.3%
Revenue YoY
93.8%
-8.7%
Net Profit YoY
338.9%
5.5%
EPS (diluted)
$0.58
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXR
AXR
LUNG
LUNG
Q1 26
$14.6M
$20.6M
Q4 25
$9.4M
$22.6M
Q3 25
$17.9M
$21.5M
Q2 25
$11.2M
$23.9M
Q1 25
$7.5M
$22.5M
Q4 24
$11.9M
$23.8M
Q3 24
$19.1M
$20.4M
Q2 24
$19.5M
$20.8M
Net Profit
AXR
AXR
LUNG
LUNG
Q1 26
$3.1M
$-13.7M
Q4 25
$1.2M
$-10.4M
Q3 25
$4.7M
$-14.0M
Q2 25
$3.9M
$-15.2M
Q1 25
$717.0K
$-14.4M
Q4 24
$4.0M
$-13.2M
Q3 24
$4.1M
$-14.1M
Q2 24
$4.1M
$-15.3M
Gross Margin
AXR
AXR
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
AXR
AXR
LUNG
LUNG
Q1 26
20.6%
-40.9%
Q4 25
11.9%
-43.8%
Q3 25
34.4%
-66.9%
Q2 25
31.7%
-62.0%
Q1 25
5.7%
-64.6%
Q4 24
26.4%
-56.5%
Q3 24
26.1%
-69.3%
Q2 24
23.9%
-75.2%
Net Margin
AXR
AXR
LUNG
LUNG
Q1 26
21.6%
-66.3%
Q4 25
12.8%
-46.1%
Q3 25
26.3%
-64.9%
Q2 25
34.8%
-63.6%
Q1 25
9.5%
-64.1%
Q4 24
33.9%
-55.4%
Q3 24
21.3%
-69.4%
Q2 24
21.2%
-73.7%
EPS (diluted)
AXR
AXR
LUNG
LUNG
Q1 26
$0.58
$-0.33
Q4 25
$0.22
$-0.25
Q3 25
$0.87
$-0.34
Q2 25
$0.73
$-0.38
Q1 25
$0.13
$-0.36
Q4 24
$0.75
$-0.33
Q3 24
$0.76
$-0.36
Q2 24
$0.77
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXR
AXR
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$50.0M
$61.6M
Total DebtLower is stronger
$21.0K
$37.3M
Stockholders' EquityBook value
$139.4M
$45.8M
Total Assets
$143.9M
$120.0M
Debt / EquityLower = less leverage
0.00×
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXR
AXR
LUNG
LUNG
Q1 26
$50.0M
$61.6M
Q4 25
$44.6M
$69.8M
Q3 25
$48.9M
$76.5M
Q2 25
$39.5M
$75.5M
Q1 25
$36.9M
$74.6M
Q4 24
$40.1M
$70.9M
Q3 24
$40.4M
$63.3M
Q2 24
$29.7M
$63.5M
Total Debt
AXR
AXR
LUNG
LUNG
Q1 26
$21.0K
$37.3M
Q4 25
$23.0K
$37.1M
Q3 25
$25.0K
$37.1M
Q2 25
$26.0K
$37.1M
Q1 25
$29.0K
$37.2M
Q4 24
$32.0K
$37.2M
Q3 24
$34.0K
$37.2M
Q2 24
$35.0K
$37.2M
Stockholders' Equity
AXR
AXR
LUNG
LUNG
Q1 26
$139.4M
$45.8M
Q4 25
$136.0M
$54.1M
Q3 25
$134.7M
$60.0M
Q2 25
$130.0M
$69.1M
Q1 25
$126.0M
$77.7M
Q4 24
$125.1M
$85.8M
Q3 24
$122.2M
$93.9M
Q2 24
$118.0M
$101.2M
Total Assets
AXR
AXR
LUNG
LUNG
Q1 26
$143.9M
$120.0M
Q4 25
$140.1M
$129.3M
Q3 25
$140.7M
$138.3M
Q2 25
$133.8M
$147.2M
Q1 25
$128.9M
$150.7M
Q4 24
$129.1M
$162.8M
Q3 24
$127.0M
$167.4M
Q2 24
$122.8M
$172.6M
Debt / Equity
AXR
AXR
LUNG
LUNG
Q1 26
0.00×
0.82×
Q4 25
0.00×
0.69×
Q3 25
0.00×
0.62×
Q2 25
0.00×
0.54×
Q1 25
0.00×
0.48×
Q4 24
0.00×
0.43×
Q3 24
0.00×
0.40×
Q2 24
0.00×
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXR
AXR
LUNG
LUNG
Operating Cash FlowLast quarter
$5.4M
Free Cash FlowOCF − Capex
$5.4M
FCF MarginFCF / Revenue
37.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$20.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXR
AXR
LUNG
LUNG
Q1 26
$5.4M
Q4 25
$-4.3M
$-7.1M
Q3 25
$9.5M
$-8.2M
Q2 25
$10.2M
$-3.9M
Q1 25
$-3.2M
$-13.2M
Q4 24
$-182.0K
$-6.7M
Q3 24
$10.7M
$-7.2M
Q2 24
$10.7M
$-5.8M
Free Cash Flow
AXR
AXR
LUNG
LUNG
Q1 26
$5.4M
Q4 25
$-4.3M
$-7.1M
Q3 25
$9.5M
$-8.3M
Q2 25
$9.7M
$-4.0M
Q1 25
$-3.3M
$-13.5M
Q4 24
$-268.0K
$-6.8M
Q3 24
$10.7M
$-7.7M
Q2 24
$10.3M
$-6.2M
FCF Margin
AXR
AXR
LUNG
LUNG
Q1 26
37.0%
Q4 25
-45.9%
-31.4%
Q3 25
53.2%
-38.4%
Q2 25
86.4%
-16.6%
Q1 25
-43.4%
-60.0%
Q4 24
-2.3%
-28.8%
Q3 24
55.8%
-37.6%
Q2 24
52.5%
-30.0%
Capex Intensity
AXR
AXR
LUNG
LUNG
Q1 26
0.1%
Q4 25
0.6%
0.1%
Q3 25
0.1%
0.4%
Q2 25
5.2%
0.2%
Q1 25
0.3%
1.3%
Q4 24
0.7%
0.5%
Q3 24
0.2%
2.0%
Q2 24
2.3%
2.3%
Cash Conversion
AXR
AXR
LUNG
LUNG
Q1 26
1.72×
Q4 25
-3.54×
Q3 25
2.03×
Q2 25
2.63×
Q1 25
-4.51×
Q4 24
-0.05×
Q3 24
2.63×
Q2 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons